Navigation Links
OM-5 Elite Urodynamics System with EMG and CO2

ProductsOM-5 Elite Urodynamics System with EMG and CO2
Company GYRUS ACMI
Item OM-5 Elite Urodynamics System with EMG and CO2
Features 
  • Seven (7) channels of data > Capable of performing H20 and CO2 cystometry, EMG, LPP, UPP, Pressure Flow Studies, and Uroflowmetry
  • Large 10.5" screen > Easy to use
  • Remote control, touch screen, on-line help, user presets > On-screen viewing during patient preparation
  • Pre-test mode > Choose the model you need
  • Eight (8) configurations > Space-saving mounting options for the smallest offices
  • Pole, wall, or cart mounts > Three to seven waveforms and data summary on one strip
Description Advanced diagnostic capabilities combined with ease of use make the OM-5 Series the best product in its class. Ideal for office or hospital-based urodynamics, the OM-5 is a complete system for Uroflowmetry, cystometry, leak point pressure, or urethral pressure profiles. Eight (8) configurations are available which make the OM-5 flexible enough to meet the needs of all clinicians. This version of the OM-5 Elite includes EMG and CO2, three H2O channels, remote control, volumetric pump, UroFlow, floppy disk drive, keyboard, and 24 MB hard drive,
Info GYRUS ACMI
Customer Service: (508) 804-2600
Web site: http://www.acmicorp.com

Related medicine products :

1. Vasculight Elite
2. Vasoseal Elite
3. NIR Elite OTW Stent System
4. NIR Elite Monorail Stent System
5. Sandman Elite
6. The Elite™ Premium Shoulder Instrument Systems
7. Apogee Elite Two-in-One Laser System
8. Elite System II
9. USA Series DUR-8 Elite Durable Flexible Ureteroscope System with Primary and Secondary Deflection
10. USA Elite System™ Rotating Continuous Flow Resectoscopes
11. USA Elite System™ MRO™-20 Rigid Percutaneous Nephroscopes
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2